Real-World Primary Care Data Comparing ALT and FIB-4 in Predicting Future Severe Liver Disease Outcomes
Background Alanine aminotransferase (ALT) has long provided a cue for chronic liver disease (CLD) diagnostic evaluation, but the Fibrosis-4 Index (FIB-4), a serologic score used for predicting advanced fibrosis risk in CLD, may provide an alternative signal. Objective Compare the predictive performance of FIB-4 with ALT for severe liver disease (SLD) events while adjusting for potential confounders. Design Retrospective cohort study of primary care electronic health record data from 2012 to 2021. Patients Adult primary care patients with at least two sets of ALT and other lab values necessary for calculating two unique FIB-4 scores, excluding those patients with an SLD prior to their index FIB-4 value. Main Measures The occurrence of an SLD event, a composite of cirrhosis, hepatocellular carcinoma, and liver transplantation, was the outcome of interest. Categories of ALT elevation and FIB-4 advanced fibrosis risk were the primary predictor variables. Multivariable logistic regression models were developed to evaluate the association of FIB-4 and ALT with SLD, and the areas under the curve (AUC) for each model were compared. Key Results The cohort of 20,828 patients included 14% with an abnormal index ALT (≥40 IU/L) and 8% with a high-risk index FIB-4 (≥2.67). During the study period, 667 (3%) patients suffered an SLD event. Adjusted multivariable logistic regression models demonstrated an association between high-risk FIB-4 (OR 19.34; 95%CI 15.50–24.13), persistently high-risk FIB-4 (OR 23.85; 95%CI 18.24–31.17), abnormal ALT (OR 7.07; 95%CI 5.81–8.59), and persistently abnormal ALT (OR 7.58; 95%CI 5.97–9.62) with SLD outcomes. The AUC of the index FIB-4 (0.847, p < 0.001) and combined FIB-4 (0.849, p < 0.001) adjusted models exceeded the index ALT adjusted model (0.815). Conclusions High-risk FIB-4 scores demonstrated superior performance compared to abnormal ALT in predicting future SLD outcomes..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Journal of general internal medicine - 38(2023), 11 vom: 22. Feb., Seite 2453-2460 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schreiner, Andrew D. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Society of General Internal Medicine 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11606-023-08093-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052911810 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052911810 | ||
| 003 | DE-627 | ||
| 005 | 20240222091213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230830s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11606-023-08093-8 |2 doi | |
| 035 | |a (DE-627)SPR052911810 | ||
| 035 | |a (SPR)s11606-023-08093-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schreiner, Andrew D. |e verfasserin |0 (orcid)0000-0003-0914-3182 |4 aut | |
| 245 | 1 | 0 | |a Real-World Primary Care Data Comparing ALT and FIB-4 in Predicting Future Severe Liver Disease Outcomes |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Society of General Internal Medicine 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background Alanine aminotransferase (ALT) has long provided a cue for chronic liver disease (CLD) diagnostic evaluation, but the Fibrosis-4 Index (FIB-4), a serologic score used for predicting advanced fibrosis risk in CLD, may provide an alternative signal. Objective Compare the predictive performance of FIB-4 with ALT for severe liver disease (SLD) events while adjusting for potential confounders. Design Retrospective cohort study of primary care electronic health record data from 2012 to 2021. Patients Adult primary care patients with at least two sets of ALT and other lab values necessary for calculating two unique FIB-4 scores, excluding those patients with an SLD prior to their index FIB-4 value. Main Measures The occurrence of an SLD event, a composite of cirrhosis, hepatocellular carcinoma, and liver transplantation, was the outcome of interest. Categories of ALT elevation and FIB-4 advanced fibrosis risk were the primary predictor variables. Multivariable logistic regression models were developed to evaluate the association of FIB-4 and ALT with SLD, and the areas under the curve (AUC) for each model were compared. Key Results The cohort of 20,828 patients included 14% with an abnormal index ALT (≥40 IU/L) and 8% with a high-risk index FIB-4 (≥2.67). During the study period, 667 (3%) patients suffered an SLD event. Adjusted multivariable logistic regression models demonstrated an association between high-risk FIB-4 (OR 19.34; 95%CI 15.50–24.13), persistently high-risk FIB-4 (OR 23.85; 95%CI 18.24–31.17), abnormal ALT (OR 7.07; 95%CI 5.81–8.59), and persistently abnormal ALT (OR 7.58; 95%CI 5.97–9.62) with SLD outcomes. The AUC of the index FIB-4 (0.847, p < 0.001) and combined FIB-4 (0.849, p < 0.001) adjusted models exceeded the index ALT adjusted model (0.815). Conclusions High-risk FIB-4 scores demonstrated superior performance compared to abnormal ALT in predicting future SLD outcomes. | ||
| 700 | 1 | |a Zhang, Jingwen |4 aut | |
| 700 | 1 | |a Moran, William P. |4 aut | |
| 700 | 1 | |a Koch, David G. |4 aut | |
| 700 | 1 | |a Livingston, Sherry |4 aut | |
| 700 | 1 | |a Bays, Chloe |4 aut | |
| 700 | 1 | |a Marsden, Justin |4 aut | |
| 700 | 1 | |a Mauldin, Patrick D. |4 aut | |
| 700 | 1 | |a Gebregziabher, Mulugeta |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of general internal medicine |d New York, NY : Springer, 1986 |g 38(2023), 11 vom: 22. Feb., Seite 2453-2460 |w (DE-627)SPR021085749 |w (DE-600)2006784-7 |x 1525-1497 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:11 |g day:22 |g month:02 |g pages:2453-2460 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11606-023-08093-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 11 |b 22 |c 02 |h 2453-2460 | ||